• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.

作者信息

Kawano Yawara, Hata Hiroyuki, Takashio Seiji, Tsujita Kenichi, Ueda Mitsuharu, Matsuoka Masao

机构信息

Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Amyloidosis Center, Kumamoto University Hospital, Kumamoto, Japan.

出版信息

Br J Haematol. 2022 Aug;198(3):e38-e41. doi: 10.1111/bjh.18234. Epub 2022 May 7.

DOI:10.1111/bjh.18234
PMID:35524546
Abstract
摘要

相似文献

1
Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松用于新诊断的与多发性骨髓瘤相关的系统性轻链淀粉样变患者
Br J Haematol. 2022 Aug;198(3):e38-e41. doi: 10.1111/bjh.18234. Epub 2022 May 7.
2
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.埃罗妥珠单抗联合来那度胺和地塞米松治疗难治性免疫球蛋白轻链淀粉样变性伴多发性骨髓瘤
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e33-e36. doi: 10.1016/j.clml.2018.08.021. Epub 2018 Sep 5.
3
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.达雷妥尤单抗：在新诊断的系统性轻链淀粉样变性中的应用评价。
Drugs. 2022 Apr;82(6):683-690. doi: 10.1007/s40265-022-01705-3.
4
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.达雷妥尤单抗、来那度胺和地塞米松治疗系统性轻链淀粉样变性：疗效高、毒性相关及1q21获得的主要不良反应
Am J Hematol. 2021 Jul 1;96(7):E253-E257. doi: 10.1002/ajh.26191. Epub 2021 May 3.
5
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.达雷妥尤单抗联合硼替佐米及地塞米松治疗新诊断的2004版梅奥分期IIIA或IIIB期轻链型淀粉样变性的疗效与安全性：一项前瞻性II期研究
Haematologica. 2024 Jul 1;109(7):2355-2358. doi: 10.3324/haematol.2024.285145.
6
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.真实世界研究达雷妥尤单抗联合方案治疗初诊轻链（AL）淀粉样变性患者。
Hematol Oncol. 2024 Jul;42(4):e3289. doi: 10.1002/hon.3289.
7
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
8
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.达雷妥尤单抗、来那度胺和地塞米松与来那度胺和地塞米松单独治疗新诊断多发性骨髓瘤（MAIA）的疗效比较：一项随机、开放标签、3 期临床试验的总生存结果。
Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.
9
Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗新诊断的依赖透析的多发性骨髓瘤患者后的肾脏恢复情况
CEN Case Rep. 2022 May;11(2):265-268. doi: 10.1007/s13730-021-00668-w. Epub 2021 Nov 24.
10
EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.EMA 审查达雷妥尤单抗（Darzalex）治疗新诊断为多发性骨髓瘤的成年患者。
Oncologist. 2020 Dec;25(12):1067-1074. doi: 10.1002/onco.13554. Epub 2020 Oct 16.

引用本文的文献

1
Monoclonal gammopathy progressing to systemic amyloidosis with cardiac involvement. A case report.单克隆丙种球蛋白病进展为累及心脏的系统性淀粉样变性。病例报告。
Arch Peru Cardiol Cir Cardiovasc. 2025 Jun 27;6(2):104-109. doi: 10.47487/apcyccv.v6i2.477. eCollection 2025 Apr-May.
2
Serum monoclonal immunoglobulin light-chain detection differs between immunofixation electrophoresis methods in patients with AL amyloidosis.血清单克隆免疫球蛋白轻链检测在 AL 淀粉样变性患者的免疫固定电泳方法之间存在差异。
Int J Hematol. 2024 Aug;120(2):212-216. doi: 10.1007/s12185-024-03790-4. Epub 2024 May 13.
3
Primary Systemic Amyloidosis: A Case Report.
原发性系统性淀粉样变：一例报告。
JNMA J Nepal Med Assoc. 2023 Oct 1;61(266):822-824. doi: 10.31729/jnma.8297.